Evidence map›Paper›PMID 35605991›Full record

ArticleMolecular pharmacology2022

Seshat M Mack, Ivone Gomes, Amanda K Fakira, Mariana L Duarte, Achla Gupta, Lloyd Fricker, Lakshmi A Devi

Open access · bronzeAbstract read
In one paragraph

Article in Molecular pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 24 citations in OpenAlex.

  1. G protein signaling capabilities at the bradykinin 2 receptor.Naunyn-Schmiedeberg's archives of pharmacology · 2026
    Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Is the Neuropeptide PEN a Ligand of GPR83?International journal of molecular sciences · 2023
    Article
  12. Article
  13. A Novel CCK Receptor GPR173 Mediates Potentiation of GABAergic Inhibition.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Seshat M MackDepartment of Pharmacological Sciences, Mount Sinai School of Medicine, United States lakshmi.devi@mssm.edu.
Ivone GomesDepartment of Pharmacology & Systems Therapeutics, Mount Sinai School of Medicine, United States.
Amanda K FakiraDepartment of Biomedical Sciences, Cooper Medical School of Rowan University, United States.
Mariana L DuartePharmacological Sciences, Icahn School of Medicine at Mount Sinai, United States.ORCID 0000-0002-1611-7102
Achla GuptaPharmacological Sciences, Icahn School of Medicine at Mount Sinai, United States.
Lloyd FrickerDepartment of Molecular Pharmacology, Albert Einstein College of Medicine, United States.
Lakshmi A DeviDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, United States lakshmi.devi@mssm.edu.ORCID 0000-0002-2179-2874
Albert Einstein College of Medicine · US

Funding

Enzymes Involved in Neuropeptide Biosynthesis, Processing and RegulationR01NS026880 · NINDS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI DEVI, LAKSHMI A · 1994 to 2019
$6.5M
Regulation Of Opioid Receptor Signaling by Endogenous PeptidesR01DA008863 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Lakshmi A Devi, Elyssa Margolis · 1995 to 2026
$6.1M
NIDA NIH HHS R01 DA008863NINDS NIH HHS R01 NS026880
6 · The paper itself

Abstract

PEN is an abundant neuropeptide that activates GPR83, a G protein-coupled receptor that is considered a novel therapeutic target due to its roles in regulation of feeding, reward, and anxiety-related behaviors. The major form of PEN in the brain is 22 residues in length. Previous studies have identified shorter forms of PEN in mouse brain and neuroendocrine cells; these shorter forms were named PEN18, PEN19 and PEN20, with the number reflecting the length of the peptide. The C-terminal five residues of PEN20 are identical to the C-terminus of a procholecystokinin (proCCK)-derived peptide, named proCCK56-62, that is present in mouse brain. ProCCK56-62 is highly conserved across species although it has no homology to the bioactive cholecystokinin domain. ProCCK56-62 and a longer form, proCCK56-63 were tested for their ability to engage GPR83. Both peptides bind GPR83 with high affinity, activate second messenger pathways, and induce ligand-mediated receptor endocytosis. Interestingly, the shorter PEN peptides, ProCC56-62, and ProCCK56-63 differentially activate signal transduction pathways. Whereas PEN22 and PEN20 facilitate receptor coupling to Gai, PEN18, PEN19 and ProCCK peptides facilitate coupling to Gas. Furthermore, the ProCCK peptides exhibit dose dependent Ga subtype selectivity in that they faciliate coupling to Gas at low concentrations and Gai at high concentrations. These data demonstrate that peptides derived from two distinct peptide precursors can differentially activate GPR83, and that GPR83 exhibits Ga subtype preference depending on the nature and concentration of the peptide. These results are consistent with the emerging idea that endogenous neuropeptides function as biased ligands.

Indexed as

Biased agonismg protein-coupled receptors (GPCRS)G protein coupled signalingG proteins

Identifiers

PMID35605991
PMCPMC9341263
OpenAlexW4281293885

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.